Mian Dopa Tablet 50/200 mg (Benserazide, Levodopa)

Adult dose

○ As with conventional levodopa therapy, initiate treatment with this drug at the lowest possible dose and increase it slowly. The dosage and administration should be determined individually at every stage of the disease. To prevent dietary protein from competing with levodopa and to promote a more rapid onset of action, it is recommended, if possible, to take this drug 30 minutes before or 1 hour after meals. Gastrointestinal adverse reactions may occur early in treatment, but can be managed by taking this drug with a low-protein meal or beverage or by increasing the dose slowly. ○ The following dosing regimens may be used as a guide to dosage and administration. 1. Initial treatment For patients with early-stage Parkinson's disease, it is preferable to initiate treatment with 1/4 tablet per dose 3-4 times daily. Patients with more advanced disease should receive twice the above dose. Once tolerability to the initial regimen has been confirmed, immediately increase the number of daily doses by 1 at weekly intervals (e.g., 4 times daily instead of 3 times daily). If the patient can be monitored closely, the dose may also be adjusted at 2-3-day intervals. Optimal effects are generally achieved with a total daily dose of 2-4 tablets of this drug, divided into 3-4 doses. If the daily dose needs to be increased further, increase it at 1-month intervals. It may take 4-6 weeks to reach the optimal dose. 2. Maintenance therapy The average maintenance dose is 1/2 tablet 4-6 times daily. The number of daily doses (at least 3 times daily) and the dosing intervals should be determined and adjusted according to the patient. 3. Special dosage and administration Antiparkinsonian drugs other than levodopa may be continued until the full therapeutic effect of this drug is achieved; however, after this drug takes effect, the doses of these drugs can often be gradually reduced. If marked fluctuations in therapeutic effect (on-off phenomenon) occur during treatment, reducing the dose per administration and increasing the dosing frequency or administering HBS capsules (levodopa/benserazide) is recommended.

This medication should not be used in patients with severe endocrine disorders. Patients with significantly impaired liver or kidney function should also avoid this drug. Patients with severe heart diseases, mental illnesses, or severe psychiatric disorders should not be administered this medication. In patients under 25 who have not completed skeletal development, this medication should not be used. If pregnancy is suspected or confirmed, the use of this medication should be discontinued immediately. Patients with malignant melanoma or a history thereof, as well as those with narrow-angle glaucoma, should also avoid this medication. Patients with allergies to this drug or its components should not use it. Patients taking non-selective MAO inhibitors should not use this drug concurrently. Patients with slightly impaired liver or kidney function, or those with open-angle glaucoma should use this medication with caution and require regular check-ups. Patients with a history of myocardial infarction, coronary artery insufficiency, or deep vein thrombosis should receive regular cardiovascular function tests. Patients with a history of osteomalacia or peptic ulcers, as well as those with diabetes, should be administered this medication cautiously and need to monitor blood sugar frequently. It is important to undergo regular blood tests and liver and kidney function tests when taking this medication for a long time. This drug can cause mental symptoms such as loss of appetite, depression, agitation, anxiety, and insomnia, particularly caution should be observed in elderly patients or those with a history of mental illness. Movement disorders or drowsiness/somnolence may occur, so caution is needed when driving or operating machinery. Symptoms such as orthostatic hypotension, nausea, vomiting, and diarrhea may appear during initial treatment, hence dosage should be adjusted according to these symptoms. Allergic skin reactions may occur rarely, and gastrointestinal bleeding or elevated liver function test results may also be observed. This medication should be discontinued before surgery, and caution is required due to potential interactions with certain drugs during anesthesia. Abrupt discontinuation of this medication may lead to symptoms similar to neuroleptic malignant syndrome, hence it should be tapered gradually. This drug has many interactions with other medications, so it is imperative to consult a healthcare professional before using this medication alongside others. It is safer for pregnant or breastfeeding women not to use this medication. In case of overdose, serious cardiovascular abnormalities, mental disorders, and gastrointestinal disorders may occur, necessitating immediate medical attention. This medication should be kept out of reach of children and stored in a sealed container as it is sensitive to moisture.

• Hemolytic anemia
• transient leukopenia
• thrombocytopenia
• loss of appetite
• depression
• agitation
• anxiety
• insomnia
• hallucinations
• delusions

This medication is sensitive to light, so it should be stored in a dark container that does not allow light in. It should also be kept away from humid areas, and stored in a cool place below 25 degrees Celsius.

Appearance

Pink round tablet with a cross score

Package unit

30 tablets/bottle, 100 tablets/bottle